GlassScriptPhysician profile
Christina Thomas
NPI 1588216840
$3,354.93
in general payments reported to CMS, 2019-2025
19 companies · $896 in 2025
The $896 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.92 · 2022: $252 · 2023: $978 · 2024: $1,183 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.01 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $334.98 | 2021-2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $325.85 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $299.34 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $253.68 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $216.95 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $211.97 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $192.98 | 2022-2025 | Auvelity |
| Lundbeck LLC | $171.09 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $159.75 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.73 | 2022-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $72.66 | 2022-2023 | Quviviq |
| Biogen, INC. | $37.50 | 2024 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $30.50 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.25 | 2025 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $24.68 | 2023 | Sublocade |
| Alfasigma USA, INC. | $21.73 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.17 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.